Abstract
The present invention relates to a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 and/or one or more inhibitors of OAT. The present invention further relates to a pharmaceutical composition comprising from about 0.5 mg to about 50 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the composition provides an in vivo plasma profile comprising a mean Tmax which is longer than about 20 minutes.
| Original language | English |
|---|---|
| IPC | C07D 498/ 02 A I |
| Patent number | US2009143335 |
| Country/Territory | Denmark |
| Priority date | 17/10/2008 |
| Priority number | US20080253879 |
| Publication status | Published - 4. Jun 2009 |
| Externally published | Yes |